A diagnosis of OCPD is only received when four out of the eight criteria are met.The eight criteria of OCPD described in the DSM-5 (of which four are required to be present in a patient for a diagnosis) are:

Preoccupation with details
Perfectionism interfering with task completion
Rigidity and stubbornness
Reluctance to delegate
Excessive conscientiousness and pedantry (excessive concern with minor details and rules)
Workaholic behavior
Miserliness (excessive desire to save money)
Unable to discard worn-out or worthless objectsThe list of criteria for the ICD-10 is similar, but does not include the last three criteria in the above list, and additionally includes the symptoms "intrusive thoughts" and "excessive doubt and caution" as criteria for diagnosis. Alternative model for diagnosis
The DSM-5 also includes an alternative set of diagnostic criteria as per the dimensional model of conceptualizing personality disorders. Under the proposed set of criteria, a person only receives a diagnosis when there is an impairment in two out of four areas of ones personality functioning, and when there are three out of four pathological traits, one of which must be rigid perfectionism. The patient must also meet the general criteria C through G for a personality disorder, which state that the traits and symptoms being displayed by the patient must be stable and unchanging over time with an onset of at least adolescence or early adulthood, visible in a variety of situations, not caused by another mental disorder, not caused by a substance or medical condition, and abnormal in comparison to a persons developmental stage and culture/religion.
After the first two periods (24 weeks), the benefit of osilodrostat was assessed by the percentage of subjects who had 24-hour urinary free cortisol levels within normal limits.In the third period (which lasted eight weeks), half of the subjects who had normal urinary free cortisol levels after 24 weeks of treatment continued taking osilodrostat and the other half was switched to placebo. Neither the subjects nor the healthcare providers know which treatment was given during this period. The benefit of osilodrostat was assessed on the percentage of subjects who had normal cortisol levels at the end of this period versus the subjects who received placebo.The FDA granted osilodrostat an orphan drug designation and granted the approval of Isturisa to Novartis. See also
Levoketoconazole

References
Further reading
Turcu A, Smith JM, Auchus R,  et al. (October 2014). "Adrenal androgens and androgen precursors-definition, synthesis, regulation and physiologic actions". Compr Physiol. 4 (4): 1369–81. doi:10.1002/cphy.c140006. ISBN 9780470650714. PMC 4437668. PMID 25428847. NIHMSID: NIHMS689229. External links
"Osilodrostat". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02697734 for "Efficacy and Safety Evaluation of Osilodrostat in Cushings Disease (LINC-4)" at ClinicalTrials.gov